Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 18Prostatic Neoplasms 6Carcinoma, Renal Cell 5Uveal Melanoma 4Sarcoma 4Histiocytoma, Malignant Fibrous 4Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Vulvar Neoplasms 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Liposarcoma 2Leukemia 2Gastrointestinal Stromal Tumors 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Carcinoma, Endometrioid 2Bone Neoplasms 2Vaginal Neoplasms 1Urogenital Neoplasms 1Ureteral Neoplasms 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

Cisplatin 11Carboplatin 7Docetaxel 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Cetuximab 5Trastuzumab 4Specimen Handling 4Radiotherapy 4Paclitaxel 4Sorafenib 3Nivolumab 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Lapatinib 3Goserelin 3Doxorubicin 3Capecitabine 3Biopsy 3sacituzumab govitecan 2darolutamide 2bicalutamide 2Radiotherapy, Intensity-Modulated 2Platinum 2Oxaliplatin 2Leuprolide 2Irinotecan 2Ipilimumab 2Dasatinib 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Salivary Gland Neoplasms × CTLA-4 Antigen × Clear all
NCT03146650 2024-01-18

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Northwestern University

Phase 2 Unknown
25 enrolled 14 charts
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡